

LIMITED TARIFF BENEFIT DISCLOSURE STATEMENT

Provide a signed hard copy to the Clerk of the Senate Committee on Finance located at 219 Dirksen SOB and a PDF version sent via email to mtb2009@finance-dem.senate.gov not later than five business days after the date of introduction of the bill. *Please be aware that this form will be made available to the public, media, and any other interested parties.*

Part I. This form is being submitted for S. 2070, which I introduced in the Senate on October 29, 2009. If the bill referenced above is a modification of a previously introduced bill to reflect technical changes, please indicate the previous bill number here: S. ____ .(Not applicable.)

Part II. Please indicate the type of disclosure below: (Please check one only)
☒ X. The bill referenced in Part I is reasonably anticipated to benefit 10 or fewer individuals or entities, and as such constitutes a Limited Tariff Benefit. (Complete Part III)
☐ ~ The bill referenced in Part I is reasonably anticipated to benefit more than 10 individuals or entities, and as such does not constitute a Limited Tariff Benefit.

Part III. Provide the information below in subparts A, B, and C if the bill referenced above is a Limited Tariff Benefit.


A. Anticipated Beneficiaries

E.I. du Pont de Nemours and Company

B. Purpose of the Limited Tariff Benefit: Financial Benefit Certification

To extend temporarily the duty suspension on phenyl (4,6-dimethoxypyrimidin-2-yl)carbamate. Suspension will support increased U.S. production; production constraints of domestic operations cannot supply demand for growth in downstream products. DuPont competitors in this market are primarily offshore; consequently, it seeks the suspension to remain competitive with them and to create additional opportunities for business growth in sulfonylurea herbicides.

X I hereby certify that neither I nor my immediate family has a financial interest in the above described limited tariff benefit.



Thomas R. Carper

November 3, 2009